TY - JOUR
AU - Noguchi,, Hiroshi
AB - Abstract Mouse monoclonal anti–human IL–2 receptor antibody (BB10) inhibits EL–2–dependent human T–cell proliferation. It has been used in clinical trials in the transplantation field and promising results are being accumulated. Mouse B–B10 antibody was humanized by grafting all CDRs and some framework amino add residues onto human antibodies, KAS for VH and PAY for Vx. Nine humanized B–BlOs with differently grafted framework residues were constructed and assessed for their biological activities. One of these humanized B–B10, M5, showed nearly the same activity as the mouse B–B10. The 49th residue of Vx was demonstrated to play a crucial role in the antigen–antibody interaction by 3–D structure analysis with a computer modeling system. This content is only available as a PDF. Author notes 2Present address: Sumitomo Pharmaceuticals Co., Ltd, Discovery Research Laboratories n, Research Center, 1–98, Kasugade-Naka 3, Kortohana-ku, Osaka 554, Japan 3Present address:Innotherapie Laboratoires, 1, Boulevard A.-Fleming, Boite Postale 1937, 25020, Besancon Cedex, France © Oxford University Press
TI - Humanization of mouse anti-human IL-2 receptor antibody B-B10
JF - Protein Engineering, Design and Selection
DO - 10.1093/protein/7.3.435
DA - 1994-03-01
UR - https://www.deepdyve.com/lp/oxford-university-press/humanization-of-mouse-anti-human-il-2-receptor-antibody-b-b10-C4DxH0s64D
SP - 435
EP - 443
VL - 7
IS - 3
DP - DeepDyve
ER -